References 1. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, et al. (2007) Long- term survival with glioblastoma multiforme. Brain 130(Pt 10): 2596–2606. 2. Perek D, Perek-Polnik M, Drogosiewicz M, Dembowska-Baginska B, Rosz- kowski M, et al. (1998) Risk factors of recurrence in 157 MB/PNET patients treated in one institution. Childs Nerv Syst 14(10): 582–586. 3. Jenkin D, Danjoux C, Greenberg M (1998) Subsequent quality of life for children irradiated for a brain tumor before age four years. Med Pediatr Oncol 31(6): 506–511. 4. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D (2011) SOX2 expression and amplification in gliomas and glioma cell lines. Cancer Genomics Proteomics 8(3): 139–147. 5. Huang X, Ketova T, Litingtung Y, Chiang C (2010) Isolation, enrichment, and maintenance of medulloblastoma stem cells. J Vis Exp (43). pii: 2086. doi(43): 10.3791/2086. 6. Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, et al. (2010) Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 29(12): 1845–1856. 7. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40(5): 499–507. 8. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, et al. (2012) Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 31: 1354–1365. 9. Wegner M, Stolt C (2005) From stem cells to neurons and glia: A soxist’s view of neural development. Trends Neurosci 28(11): 583–8. 10. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19): 7011–7021. 11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432(7015): 396– 401. 12. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, et al. (2011) Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 6(11): e26740. 13. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, et al. (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27(1): 40–48. 14. Bylund M, Andersson E, Novitch BG, Muhr J (2003) Vertebrate neurogenesis is counteracted by Sox1–3 activity. Nat Neurosci 6(11): 1162–1168. 15. Graham V, Khudyakov J, Ellis P, Pevny L (2003) SOX2 functions to maintain neural progenitor identity. Neuron 39(5): 749–765. 16. Kopp JL, Ormsbee BD, Desler M, Rizzino A (2008) Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 26(4): 903–911. 17. Chew J, Loh Y, Zhang W, Chen X, Tam W, et al. (2005) Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 25(14): 6031–46. 18. Chen Y, Shi L, Zhang L, Li R, Liang J, et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283(26): 17969–17978. 19. Jia X, Li X, Xu Y, Zhang S, Mou W, et al. (2011) SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 3(4): 230–238. 20. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, et al. (2011) SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 91(12): 1796–1804. 21. Kingsley-Kallesen M, Luster TA, Rizzino A. (2001) Transcriptional regulation of the transforming growth factor-beta2 gene in glioblastoma cells. In Vitro Cell Dev Biol Anim 37(10): 684–690. SOX2 Controls Fate of Brain Tumor Cells 22. Cox JL, Mallanna SK, Ormsbee BD, Desler M, Wiebe MS, et al. (2011) Banf1 is required to maintain the self-renewal of both mouse and human embryonic stem cells. J Cell Sci 124: 2654–2665. 23. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2): 55–63. 24. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/ cell kill. J Immunol Methods 119(2): 203–210. 25. Mallanna SK, Ormsbee BD, Iacovino M, Gilmore JM, Cox JL, et al. (2010) Proteomic analysis of Sox2-associated proteins during early stages of mouse embryonic stem cell differentiation identifies Sox21 as a novel regulator of stem cell fate. Stem Cells 28(10): 1715–1727. 26. Telford WG, King LE, Fraker PJ (1991) Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif 24(5): 447–459. 27. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, et al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100(25): 15178–15183. 28. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63(18): 5821–5828. 29. Son MJ, Woolard K, Nam DH, Lee J, Fine HA (2009) SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4(5): 440–452. 30. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92(20): 9363–9367. 31. Christensen K, Schroder HD, Kristensen BW (2011) CD133(+) niches and single cells in glioblastoma have different phenotypes. J Neurooncol 104(1): 129–143. 32. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1): 44–57. 33. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1): 1–13. 34. Engelkamp D, Rashbass P, Seawright A, van Heyningen V (1999) Role of Pax6 in development of the cerebellar system. Development 126(16): 3585–3596. 35. Riederer BM, Draberova E, Viklicky V, Draber P (1995) Changes of MAP2 phosphorylation during brain development. J Histochem Cytochem 43(12): 1269–1284. 36. McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, et al. (2009) Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro. Mol Cancer Res 7(4): 489–497. 37. Fang X, Yoon JG, Li L, Yu W, Shao J, et al. (2011) The SOX2 response program in glioblastoma multiforme: An integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics 12: 11. 38. Jeong CH, Cho YY, Kim MO, Kim SH, Cho EJ, et al. (2010) Phosphorylation of Sox2 cooperates in reprogramming to pluripotent stem cells. Stem Cells 28(12): 2141–2150. 39. Tsuruzoe S, Ishihara K, Uchimura Y, Watanabe S, Sekita Y, et al. (2006) Inhibition of DNA binding of Sox2 by the SUMO conjugation. Biochem Biophys Res Commun 351(4): 920–926. 40. Zhao HY, Zhang YJ, Dai H, Zhang Y, Shen YF (2011) CARM1 mediates modulation of Sox2. PLoS One 6(10): e27026. 41. Baltus GA, Kowalski MP, Zhai H, Tutter AV, Quinn D, et al. (2009) Acetylation of sox2 induces its nuclear export in embryonic stem cells. Stem Cells 27(9): 2175–2184. PLOS ONE | www.plosone.org 14 August 2012 | Volume 7 | Issue 8 | e44087